News

Lupin gets US FDA nod to market bacterial infection drug

The drug is the generic version of sulfamethoxazole, trimethoprim oral suspension

Homegrown pharma major Lupin has received approval from the US health regulator to market its generic version of sulfamethoxazole and trimethoprim oral suspension used to treat bacterial infections. 

THIS CAN BE YOUR ADVERTISEMENT

The approval by the United States Food and Drug Administration (US FDA) is for the strength of 200 mg/40 mg per 5 ml, a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, the company said in a regulatory filing.

Sulfamethoxazole and trimethoprim oral suspension, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).

Citing IQVIA MAT September 2020 data, the company said the sulfamethoxazole and trimethoprimoral suspension had estimated annual sales of approximately $19 million in the US. 

PTI

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close